Global Medical Nuclide Products Market Strategic Research Report

Scope of the Report

The global Medical Nuclide Products market size is predicted to grow from US$ 11,470 million in 2025 to US$ 20,850 million in 2032; it is expected to grow at a CAGR of 9.0% from 2026 to 2032.

Medical nuclide products refer to medical preparations or devices containing radioactive isotopes, which achieve diagnostic or therapeutic functions through the radiation released by their decay. Such products must strictly comply with radioactive safety standards and are widely used in the field of nuclear medicine. For example, imaging agents used in diagnosis assist in disease detection through gamma-ray imaging, and iodine-131 and lutetium-177 used in treatment destroy diseased tissues through targeted radiation. Their production, quality control and clinical use are subject to the dual constraints of national nuclear safety regulations and the drug regulatory system to ensure patient safety and the effectiveness of diagnosis and treatment.

The global medical nuclide products market is being driven by the growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions, which require precise diagnostic imaging and targeted radiopharmaceutical therapies. Technological advancements in nuclear imaging modalities like PET and SPECT, combined with the increasing adoption of theranostic approaches, have significantly expanded clinical applications for medical nuclides. In addition, favorable government initiatives to promote nuclear medicine infrastructure, and increasing investment in radioisotope production facilities, particularly in developing regions, are further accelerating market growth.

Despite its potential, the medical nuclide products market faces several challenges. The short half-life of many radioisotopes requires localized and timely production, which puts pressure on logistics and supply chain networks, especially in geographically dispersed regions. Regulatory complexities surrounding the handling, transport, and storage of radioactive materials also increase operational burden. Moreover, a global shortage of key isotopes like Mo-99, and limited access to cyclotrons and nuclear reactors in many countries, hampers consistent supply. High costs and the scarcity of trained nuclear medicine professionals further constrain market expansion in certain areas.

This report presents a comprehensive overview of the global Medical Nuclide Products market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Technetium-99m
• Fluorine-18
• Gallium-68
• Iodine-123
• Indium-111
• Copper-64
• Xenon-133
• Iodine-131
• Yttrium-90
• Lutetium-177
• Strontium-89
• Samarium-153
• Radium-223
• Iodine-125
• Other

Segment by Product

• Therapeutic Nuclear Medicine
• Diagnostic Nuclear Medicine

Segment by players, this report covers

• Cardinal Health
• GE Healthcare
• Lantheus Medical Imaging
• Bayer
• Eli Lilly
• Bracco Imaging
• Curium Pharma
• Jubilant Pharmova
• Aurobindo Pharma
• Novartis
• Siemens
• NTP Radioisotopes
• ANSTO
• Polatom
• China Isotope & Radiation
• Yantai Dongcheng Pharmaceutical
• Saide Biotechnology

Segment by Application

• Cancer
• Cardiovascular Disease
• Bone and Joint Disease
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Medical Nuclide Products market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Cancer, Cardiovascular Disease, Bone and Joint Disease evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact